Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study

Oscar Hou In Chou; Jiandong Zhou; Teddy Tai Loy Lee; Thompson Kot; Sharen Lee; Abraham Ka Chung Wai; Wing Tak Wong; Qingpeng Zhang; Shuk Han Cheng; Tong  Liu; Vassilios S. Vassiliou; Bernard Man Yung Cheung; Gary Tse

doi:10.1007/s00392-022-02007-0

Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study

Oscar Hou In Chou
, Jiandong Zhou
, Teddy Tai Loy Lee
, Thompson Kot
, Sharen Lee
, Abraham Ka Chung Wai
, Wing Tak Wong
, Qingpeng Zhang
, Shuk Han Cheng
, Tong Liu
, Vassilios S. Vassiliou^*
, Bernard Man Yung Cheung^*
, Gary Tse^*

^*Corresponding author for this work

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

27 Citations (Scopus)

50 Downloads (CityUHK Scholars)

Abstract

Background Both COVID-19 infection and COVID-19 vaccines have been associated with the development of myopericarditis. The objective of this study is to (1) analyse the rates of myopericarditis after COVID-19 infection and COVID-19 vaccination in Hong Kong, (2) compared to the background rates, and (3) compare the rates of myopericarditis after COVID-19 vaccination to those reported in other countries.

Methods This was a population-based cohort study from Hong Kong, China. Patients with positive RT-PCR test for COVID-19 between 1st January 2020 and 30th June 2021 or individuals who received COVID-19 vaccination until 31st August were included. The main exposures were COVID-19 positivity or COVID-19 vaccination. The primary outcome was myopericarditis.

Results This study included 11,441 COVID-19 patients from Hong Kong, four of whom suffered from myopericarditis (rate per million: 326; 95% confidence interval [CI] 127-838). The rate was higher than the pre-COVID-19 background rate in 2019 (rate per million: 5.5, 95% CI 4.1-7.4) with a rate ratio of 55.0 (95% CI 21.4-141). Compared to the background rate, the rate of myopericarditis among vaccinated subjects in Hong Kong was similar (rate per million: 5.5; 95% CI 4.1-7.4) with a rate ratio of 0.93 (95% CI 0.69-1.26). The rates of myocarditis after vaccination in Hong Kong were comparable to those vaccinated in the United States, Israel, and the United Kingdom.

Conclusions COVID-19 infection was associated with significantly higher rate of myopericarditis compared to the vaccine-associated myopericarditis.

Original language	English
Pages (from-to)	1098–1103
Number of pages	6
Journal	Clinical Research in Cardiology
Volume	111
Issue number	10
Online published	25 Mar 2022
DOIs	https://doi.org/10.1007/s00392-022-02007-0
Publication status	Published - Oct 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Keywords

COVID-19
Myocarditis
Myopericarditis
Pericarditis
Vaccine

Publisher's Copyright Statement

This full text is made available under CC-BY 4.0. https://creativecommons.org/licenses/by/4.0/

Access Output

10.1007/s00392-022-02007-0

97606909.pdfFinal Published version, 838 KBLicence: CC BY

Other Access Options

Check CityUHK Library

Permanent Link

Right click to copy link

Cite this

Chou, O. H. I., Zhou, J., Lee, T. T. L., Kot, T., Lee, S., Wai, A. K. C., Wong, W. T., Zhang, Q., Cheng, S. H., Liu, T., Vassiliou, V. S., Cheung, B. M. Y., & Tse, G. (2022). Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study. Clinical Research in Cardiology, 111(10), 1098–1103. https://doi.org/10.1007/s00392-022-02007-0

@article{dda810d6ec3345d89547d0996919d3ae,

title = "Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study",

abstract = "Background Both COVID-19 infection and COVID-19 vaccines have been associated with the development of myopericarditis. The objective of this study is to (1) analyse the rates of myopericarditis after COVID-19 infection and COVID-19 vaccination in Hong Kong, (2) compared to the background rates, and (3) compare the rates of myopericarditis after COVID-19 vaccination to those reported in other countries. Methods This was a population-based cohort study from Hong Kong, China. Patients with positive RT-PCR test for COVID-19 between 1st January 2020 and 30th June 2021 or individuals who received COVID-19 vaccination until 31st August were included. The main exposures were COVID-19 positivity or COVID-19 vaccination. The primary outcome was myopericarditis. Results This study included 11,441 COVID-19 patients from Hong Kong, four of whom suffered from myopericarditis (rate per million: 326; 95\% confidence interval [CI] 127-838). The rate was higher than the pre-COVID-19 background rate in 2019 (rate per million: 5.5, 95\% CI 4.1-7.4) with a rate ratio of 55.0 (95\% CI 21.4-141). Compared to the background rate, the rate of myopericarditis among vaccinated subjects in Hong Kong was similar (rate per million: 5.5; 95\% CI 4.1-7.4) with a rate ratio of 0.93 (95\% CI 0.69-1.26). The rates of myocarditis after vaccination in Hong Kong were comparable to those vaccinated in the United States, Israel, and the United Kingdom. Conclusions COVID-19 infection was associated with significantly higher rate of myopericarditis compared to the vaccine-associated myopericarditis.",

keywords = "COVID-19, Myocarditis, Myopericarditis, Pericarditis, Vaccine",

author = "Chou, \{Oscar Hou In\} and Jiandong Zhou and Lee, \{Teddy Tai Loy\} and Thompson Kot and Sharen Lee and Wai, \{Abraham Ka Chung\} and Wong, \{Wing Tak\} and Qingpeng Zhang and Cheng, \{Shuk Han\} and Tong Liu and Vassiliou, \{Vassilios S.\} and Cheung, \{Bernard Man Yung\} and Gary Tse",

year = "2022",

month = oct,

doi = "10.1007/s00392-022-02007-0",

language = "English",

volume = "111",

pages = "1098–1103",

journal = "Clinical Research in Cardiology",

issn = "1861-0684",

publisher = "Taylor \& Francis",

number = "10",

}

Chou, OHI, Zhou, J, Lee, TTL, Kot, T, Lee, S, Wai, AKC, Wong, WT, Zhang, Q, Cheng, SH, Liu, T, Vassiliou, VS, Cheung, BMY & Tse, G 2022, 'Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study', Clinical Research in Cardiology, vol. 111, no. 10, pp. 1098–1103. https://doi.org/10.1007/s00392-022-02007-0

Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study. / Chou, Oscar Hou In; Zhou, Jiandong; Lee, Teddy Tai Loy et al.
In: Clinical Research in Cardiology, Vol. 111, No. 10, 10.2022, p. 1098–1103.

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

TY - JOUR

T1 - Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines

T2 - a population-based study

AU - Chou, Oscar Hou In

AU - Zhou, Jiandong

AU - Lee, Teddy Tai Loy

AU - Kot, Thompson

AU - Lee, Sharen

AU - Wai, Abraham Ka Chung

AU - Wong, Wing Tak

AU - Zhang, Qingpeng

AU - Cheng, Shuk Han

AU - Liu, Tong

AU - Vassiliou, Vassilios S.

AU - Cheung, Bernard Man Yung

AU - Tse, Gary

PY - 2022/10

Y1 - 2022/10

N2 - Background Both COVID-19 infection and COVID-19 vaccines have been associated with the development of myopericarditis. The objective of this study is to (1) analyse the rates of myopericarditis after COVID-19 infection and COVID-19 vaccination in Hong Kong, (2) compared to the background rates, and (3) compare the rates of myopericarditis after COVID-19 vaccination to those reported in other countries. Methods This was a population-based cohort study from Hong Kong, China. Patients with positive RT-PCR test for COVID-19 between 1st January 2020 and 30th June 2021 or individuals who received COVID-19 vaccination until 31st August were included. The main exposures were COVID-19 positivity or COVID-19 vaccination. The primary outcome was myopericarditis. Results This study included 11,441 COVID-19 patients from Hong Kong, four of whom suffered from myopericarditis (rate per million: 326; 95% confidence interval [CI] 127-838). The rate was higher than the pre-COVID-19 background rate in 2019 (rate per million: 5.5, 95% CI 4.1-7.4) with a rate ratio of 55.0 (95% CI 21.4-141). Compared to the background rate, the rate of myopericarditis among vaccinated subjects in Hong Kong was similar (rate per million: 5.5; 95% CI 4.1-7.4) with a rate ratio of 0.93 (95% CI 0.69-1.26). The rates of myocarditis after vaccination in Hong Kong were comparable to those vaccinated in the United States, Israel, and the United Kingdom. Conclusions COVID-19 infection was associated with significantly higher rate of myopericarditis compared to the vaccine-associated myopericarditis.

AB - Background Both COVID-19 infection and COVID-19 vaccines have been associated with the development of myopericarditis. The objective of this study is to (1) analyse the rates of myopericarditis after COVID-19 infection and COVID-19 vaccination in Hong Kong, (2) compared to the background rates, and (3) compare the rates of myopericarditis after COVID-19 vaccination to those reported in other countries. Methods This was a population-based cohort study from Hong Kong, China. Patients with positive RT-PCR test for COVID-19 between 1st January 2020 and 30th June 2021 or individuals who received COVID-19 vaccination until 31st August were included. The main exposures were COVID-19 positivity or COVID-19 vaccination. The primary outcome was myopericarditis. Results This study included 11,441 COVID-19 patients from Hong Kong, four of whom suffered from myopericarditis (rate per million: 326; 95% confidence interval [CI] 127-838). The rate was higher than the pre-COVID-19 background rate in 2019 (rate per million: 5.5, 95% CI 4.1-7.4) with a rate ratio of 55.0 (95% CI 21.4-141). Compared to the background rate, the rate of myopericarditis among vaccinated subjects in Hong Kong was similar (rate per million: 5.5; 95% CI 4.1-7.4) with a rate ratio of 0.93 (95% CI 0.69-1.26). The rates of myocarditis after vaccination in Hong Kong were comparable to those vaccinated in the United States, Israel, and the United Kingdom. Conclusions COVID-19 infection was associated with significantly higher rate of myopericarditis compared to the vaccine-associated myopericarditis.

KW - COVID-19

KW - Myocarditis

KW - Myopericarditis

KW - Pericarditis

KW - Vaccine

UR - https://www.scopus.com/pages/publications/85127516840

UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-85127516840&origin=recordpage

U2 - 10.1007/s00392-022-02007-0

DO - 10.1007/s00392-022-02007-0

M3 - RGC 21 - Publication in refereed journal

C2 - 35333945

SN - 1861-0684

VL - 111

SP - 1098

EP - 1103

JO - Clinical Research in Cardiology

JF - Clinical Research in Cardiology

IS - 10

ER -

Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study

Abstract

UN SDGs

Research Keywords

Publisher's Copyright Statement

Access Output

Other Access Options

Permanent Link

Other Files and Links

Fingerprint

Cite this